Navigation Links
Anesiva Announces First Quarter 2008 Financial Results
Date:5/8/2008

mpany's progress and future outlook. Interested parties can listen to the live conference call by dialing 866-616-3642 (international dial: 706-643-3817) or by logging on to http://www.anesiva.com and going to the Investor Information page. For those unable to participate via the Internet, a replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 45132379. The webcast will be available until the company's next quarterly financial results conference call.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), reduces pain after only a single administration for weeks to months based on mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may,
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Pacific Northwest ... Summary Global Markets Direct,s, ,Pacific Northwest ... provides an overview of the Pacific Northwest Biotechnology, ... report provides comprehensive information on the current therapeutic ... with comparative analysis at various stages, therapeutics assessment ...
(Date:9/30/2014)... Over the last decade, the laboratory ... R&D budgets and increased acceptance of new filtration technologies ... biotechnology industries are also catalyzing the growth of laboratory ... expected to grow at a strong CAGR during the ... worth $2,532.6 million by 2019. The market is mainly ...
(Date:9/30/2014)... -- CORD:USE Cord Blood Bank – www.corduse.com ... into an Equity and Exclusive Services Agreement with Tianhe Stem ... patented technologies for the isolation of human cord blood-derived ... performing Phase I/II clinical trials in China ... Tianhe,s Stem Cell Educator Therapy showing that the therapy ...
(Date:9/30/2014)... Iowa , Sept. 30, 2014  KemPharm, ... the discovery and development of proprietary new molecular ... States Patent and Trademark Office (USPTO) issued U.S. ... application entitled, "Benzoic Acid, Benzoic Acid Derivatives and ... of Making and Use Thereof." The ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... Seamless Performance Between GeneChip Scanner 3000 ... , ... GeneChip Instrument System is the most advanced microarray analysis platform ... array manufacturing processes have enabled Affymetrix to produce expression probe arrays with ...
... Spectrometry Application Note , Melissa ... Introduction , ... complex mixtures is one of the key objectives for the use of ... ion trap systems, such as the Finnigan LCQ Deca XP Plus and ...
... Chromatography and Mass Spectrometry Application Note , ... Quantum Discovery Enhanced Mass- Resolution , Xiaoying ... Walter Korfmacher 1 , ... NJ, USA; 2 Thermo Electron Corporation, Somerset, NJ, USA , ...
Cached Biology Technology:The New Affymetrix GeneChip Scanner 3000 2The New Affymetrix GeneChip Scanner 3000 3The New Affymetrix GeneChip Scanner 3000 4The New Affymetrix GeneChip Scanner 3000 5The New Affymetrix GeneChip Scanner 3000 6The New Affymetrix GeneChip Scanner 3000 7The New Affymetrix GeneChip Scanner 3000 8The New Affymetrix GeneChip Scanner 3000 9The New Affymetrix GeneChip Scanner 3000 10The New Affymetrix GeneChip Scanner 3000 11The New Affymetrix GeneChip Scanner 3000 12The New Affymetrix GeneChip Scanner 3000 13The New Affymetrix GeneChip Scanner 3000 14The New Affymetrix GeneChip Scanner 3000 15Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 2Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 3Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 4Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 2Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 3Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 4Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 5Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery 6
(Date:9/30/2014)... of Health (NIH) awarded Lawrence Livermore National Laboratory ... array system that will enable researchers to better ... and scale. , LLNL,s grant-funded project is part ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... understanding of the human mind and uncover ways ...
(Date:9/30/2014)... of environmental scientists and engineers, led by Clemson ... three-year, $5.25 million grant from the U.S. Department ... to make a direct positive impact on South ... disposal of radioactive contaminants. , "Understanding the scientific ... with environmental aspects of nuclear technologies is imperative ...
(Date:9/30/2014)... Medicine reports positive results of a phase 1 ... of lung cancer marked by rearrangement of the gene ... advanced non-small cell lung cancer testing positive for ROS1 ... 3 complete responses and 33 partial responses. Median progression-free ... to resume its growth after being slowed by treatment ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... little research has been done on it, now may have ... involving people, the acai (ah-sigh-EE) berry has proven its ability ... as juice and pulp. That finding, by a team of ... of the Journal of Agricultural and Food Chemistry ., ...
... a chance to take root and spread, scientists are ... prevention. Leading experts from around the globe are gathering ... promising new field, with the hope this work will ... you take advantage of the meeting,s scientific abstracts and ...
... al.report in the Journal of Cell Biology ... movement in tumor cells., On 2D surfaces, cells may ... the cell to the extracellular matrix, are known to ... been unclear. Recent work has suggested that an integrin ...
Cached Biology News:Research shows Brazilian acai berry antioxidants absorbed by human body 2Research shows Brazilian acai berry antioxidants absorbed by human body 3